Search our Database of Scientific Publications and Authors

I’m looking for a

    8104 results match your criteria Alimentary Pharmacology and Therapeutics[Journal]

    1 OF 163

    Significant burden of nonalcoholic fatty liver disease with advanced fibrosis in the US: a cross-sectional analysis of 2011-2014 National Health and Nutrition Examination Survey.
    Aliment Pharmacol Ther 2017 Sep 15. Epub 2017 Sep 15.
    Division of Gastroenterology and Hepatology, Alameda Health System, Highland Hospital, Oakland, CA, USA.
    Background: Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease in the US. Understanding the epidemiology of NAFLD, with specific focus on individuals with hepatic fibrosis is important to guide healthcare resource planning.

    Aim: To evaluate prevalence and predictors of hepatic fibrosis among US adults with NAFLD. Read More

    Risk factors for thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype.
    Aliment Pharmacol Ther 2017 Sep 15. Epub 2017 Sep 15.
    Department of Gastroenterology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
    Background: Leucopenia is a common side effect in patients treated with thiopurines. Variants in the thiopurine S-methyltransferase (TPMT) gene are the best-known risk factor, but only explain up to 25% of leucopenia cases.

    Aim: To identify the clinical risk factors for thiopurine-induced leucopenia in patients without a common TPMT variant, and explore if these patients are at increased risk for infections. Read More

    Review article: next-generation transformative advances in the pathogenesis and management of autoimmune hepatitis.
    Aliment Pharmacol Ther 2017 Sep 13. Epub 2017 Sep 13.
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN, USA.
    Background: Advances in autoimmune hepatitis that transform current concepts of pathogenesis and management can be anticipated as products of ongoing investigations driven by unmet clinical needs and an evolving biotechnology.

    Aim: To describe the advances that are likely to become transformative in autoimmune hepatitis, based on the direction of current investigations.

    Methods: Pertinent abstracts were identified in PubMed by multiple search terms. Read More

    Systematic review with meta-analysis: the global recurrence rate of Helicobacter pylori.
    Aliment Pharmacol Ther 2017 Sep 11. Epub 2017 Sep 11.
    Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
    Background: Up-to-date information regarding the recurrence rate of Helicobacter pylori (H. pylori) after eradication therapy is not available.

    Aim: To evaluate the global recurrence rate following H. Read More

    Review article: the diagnostic approach and current management of chylous ascites.
    Aliment Pharmacol Ther 2017 Sep 11. Epub 2017 Sep 11.
    GI/Liver Unit, Institute of Digestive Diseases and Metabolism, University of Barcelona, Hospital Clinic and Institut d'Investigacions Biomèdiques August Pi-Sunyer (IDIBAPS), Barcelona, Spain.
    Background: Chylous ascites is rare, accounting for less than 1% of cases. An appropriate and stepwise approach to its diagnosis and management is of key importance.

    Aim: To review the current diagnostic approach and management of chylous ascites. Read More

    Systematic review with meta-analysis: breastfeeding and the risk of Crohn's disease and ulcerative colitis.
    Aliment Pharmacol Ther 2017 Sep 11. Epub 2017 Sep 11.
    Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, USA.
    Background: Breastfeeding is a modifiable factor that may influence development of inflammatory bowel diseases. However, literature on this has been inconsistent and not accounted for heterogeneity in populations and exposure.

    Aim: To conduct a meta-analysis to examine the association between breastfeeding in infancy and risk of Crohn's disease (CD) and ulcerative colitis (UC). Read More

    Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial.
    Aliment Pharmacol Ther 2017 Sep 8. Epub 2017 Sep 8.
    Minato-Ku, Tokyo, Japan.
    Background: Significance of monitoring adalimumab trough levels and anti-adalimumab antibodies (AAA) for disease outcome in Crohn's disease (CD) patients remained unclear.

    Aim: To evaluate the association of adalimumab trough levels and AAA at week 26 with clinical remission at week 52, the effect of azathiopurine on AAA and factors influencing trough levels in CD patients in the DIAMOND trial.

    Methods: We performed this study using adalimumab trough levels, AAA at week 26 and 6-thioguanine nucleotide (TGN) in red blood cells at week 12. Read More

    Review article: transient receptor potential channels as possible therapeutic targets in irritable bowel syndrome.
    Aliment Pharmacol Ther 2017 Sep 8. Epub 2017 Sep 8.
    Division of Gastroenterology-Hepatology, Department of Internal Medicine, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, Maastricht, Limburg, The Netherlands.
    Background: Abdominal pain in irritable bowel syndrome (IBS) remains challenging to treat effectively. Researchers have attempted to elucidate visceral nociceptive processes in order to guide treatment development. Transient receptor potential (TRP) channels have been implied in the generation (TRPV1, TRPV4, TRPA1) and inhibition (TRPM8) of visceral pain signals. Read More

    Ribavirin steady-state plasma level is a predictor of sustained virological response in hepatitis C-infected patients treated with direct-acting antivirals.
    Aliment Pharmacol Ther 2017 Sep 7. Epub 2017 Sep 7.
    Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center, Amsterdam, The Netherlands.
    Background: In the era of highly effective direct-acting antivirals (DAAs) for treatment of patients with chronic hepatitis C virus (HCV) infection, ribavirin (RBV) is still considered beneficial in certain patients.

    Aim: To assess the association between RBV steady-state plasma levels and sustained virological response (SVR).

    Methods: Consecutive HCV-infected patients treated with DAAs plus RBV from four Dutch academic medical centres were enrolled. Read More

    The body composition profile is associated with response to anti-TNF therapy in Crohn's disease and may offer an alternative dosing paradigm.
    Aliment Pharmacol Ther 2017 Sep 7. Epub 2017 Sep 7.
    Inflammatory bowel disease Unit, St Mark's Hospital, Middlesex, Harrow, UK.
    Background: Anti-tumour necrosis factor (TNF)s form a major part of therapy in Crohn's disease and have a primary nonresponse rate of 10%-30% and a secondary loss of response rate of 5% per year. Myopenia is prevalent in Crohn's disease and is measured using body composition analysis tools.

    Aim: To test the hypothesis that body composition can predict outcomes of anti-TNF primary nonresponse and secondary loss of response. Read More

    Reduced risk of decompensation and death associated with use of statins in patients with alcoholic cirrhosis. A nationwide case-cohort study.
    Aliment Pharmacol Ther 2017 Oct;46(7):673-680
    Gastrounit, Medical Section, University Hospital of Hvidovre, Hvidovre, Denmark.
    Background: Reports have indicated that the use of statins may ameliorate the course of cirrhosis.

    Aim: To determine the relationship between use of statins and mortality rate in patients with cirrhosis.

    Methods: We did a retrospective case-cohort analysis based on data from the Danish registers from the period 1995 through 2014. Read More

    Food elimination diets are effective for long-term treatment of adults with eosinophilic oesophagitis.
    Aliment Pharmacol Ther 2017 Sep 6. Epub 2017 Sep 6.
    Division of Gastroenterology and Hepatology, Department of Medicine, Center for Esophageal Diseases and Swallowing, and Center for Gastrointestinal Biology and Disease, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
    Background: Limited data describe the long-term efficacy of dietary elimination in eosinophilic oesophagitis (EoE).

    Aim: To assess the long-term outcomes of food elimination diets for treatment of adults with EoE.

    Methods: We conducted a retrospective cohort study at our centre analysing all EoE patients receiving a food elimination diet without concomitant steroids. Read More

    Systematic review with meta-analysis: the association between hepatitis E seroprevalence and haemodialysis.
    Aliment Pharmacol Ther 2017 Sep 4. Epub 2017 Sep 4.
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
    Background: Hepatitis E virus (HEV) infection appears to be more common than previously thought. HEV seroprevalence in patients on maintenance haemodialysis (HD) is unclear with a range from 0% to 44%. In addition, risk factors of transmission of HEV in patients on haemodialysis are unknown. Read More

    Review article: the human intestinal virome in health and disease.
    Aliment Pharmacol Ther 2017 Sep 4. Epub 2017 Sep 4.
    Department of Surgery and Cancer, Imperial College London, London, UK.
    Background: The human virome consists of animal-cell viruses causing transient infections, bacteriophage (phage) predators of bacteria and archaea, endogenous retroviruses and viruses causing persistent and latent infections. High-throughput, inexpensive, sensitive sequencing methods and metagenomics now make it possible to study the contribution dsDNA, ssDNA and RNA virus-like particles make to the human virome, and in particular the intestinal virome.

    Aim: To review and evaluate the pioneering studies that have attempted to characterise the human virome and generated an increased interest in understanding how the intestinal virome might contribute to maintaining health, and the pathogenesis of chronic diseases. Read More

    Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period.
    Aliment Pharmacol Ther 2017 Aug 31. Epub 2017 Aug 31.
    Service Hépatogastroentérologie, Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpétrière - Université Pierre et Marie Curie, UMR_S 938, INSERM - CDR Saint Antoine, Paris, France.
    Background: Non-alcoholic fatty liver disease (NAFLD) is an increasing cause of hepatocellular carcinoma (HCC) worldwide. NAFLD-HCC often occurs in noncirrhotic liver raising important surveillance issues.

    Aim: To determine the temporal trends for prevalence, clinical characteristics and outcomes of NAFLD-HCC in patients undergoing liver resection. Read More

    Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy.
    Aliment Pharmacol Ther 2017 Aug 24. Epub 2017 Aug 24.
    Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.
    Background: Rifaximin might decrease the risk of portal hypertension-related complications by controlling small intestinal bacterial overgrowth.

    Aim: To evaluate whether rifaximin was associated with the risk of death and cirrhotic complications.

    Methods: We conducted a retrospective study that included 1042 patients experiencing hepatic encephalopathy (HE): 421 patients without hepatocellular carcinoma (HCC; the non-HCC cohort) and 621 patients with HCC (the HCC cohort). Read More

    Systematic review: cost-effectiveness of direct-acting antivirals for treatment of hepatitis C genotypes 2-6.
    Aliment Pharmacol Ther 2017 Oct 24;46(8):711-721. Epub 2017 Aug 24.
    Institute for Technology Assessment, Massachusetts General Hospital, Boston, MA, USA.
    Background: The availability of direct-acting antivirals (DAAs) has dramatically changed the landscape of hepatitis C virus (HCV) therapy; however, the cost and budget requirements for DAA treatment have been widely debated.

    Aims: To systematically review published studies evaluating the cost-effectiveness of DAAs for HCV genotype 2-6 infections, and synthesise and re-evaluate results with updated drug prices.

    Methods: We conducted a systematic search of various electronic databases, including Medline, EMBASE, Cochrane library and EconLit for cost-effectiveness studies published from 2011 to 2016. Read More

    The higher prevalence of truncal obesity and diabetes in American than Chinese patients with chronic hepatitis C might contribute to more rapid progression to advanced liver disease.
    Aliment Pharmacol Ther 2017 Oct 22;46(8):731-740. Epub 2017 Aug 22.
    Peking University Hepatology Institute, Peking University People's Hospital, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing, China.
    Background: Chronic hepatitis C virus (HCV) infection is the leading cause of cirrhosis and hepatocellular carcinoma (HCC) in the United States (US) and an emerging cause in China.

    Aim: To compare the clinical characteristics of hepatitis C patients in the US and China, and factors influencing disease stage.

    Methods: Prospective study of 2 cohorts of HCV patients recruited at 1 site in the US and 3 sites in China. Read More

    Changes in medical management and colectomy rates: a population-based cohort study on the epidemiology and natural history of ulcerative colitis in Örebro, Sweden, 1963-2010.
    Aliment Pharmacol Ther 2017 Oct 17;46(8):748-757. Epub 2017 Aug 17.
    Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
    Background: Whether the epidemiology of ulcerative colitis (UC) has changed during recent decades is partly unknown.

    Aim: To depict temporal trends in the epidemiology and medical treatment of UC as well as the long-term risk of progression in disease extent and colectomy, during 1963-2010.

    Methods: Patients were identified by evaluation of all medical records in the archive of the Colitis Clinic, Örebro University Hospital. Read More

    Systematic review with meta-analysis: enteral nutrition therapy for the induction of remission in paediatric Crohn's disease.
    Aliment Pharmacol Ther 2017 Oct 16;46(7):645-656. Epub 2017 Aug 16.
    Teachers College, Columbia University, New York, NY, USA.
    Background: Despite potential adverse-events in a paediatric population, corticosteroids are used to induce remission in paediatric Crohn's disease. Exclusive enteral nutrition also induces remission, but is infrequently used in the USA because corticosteroids are considered the superior therapy. New data have become available since the publication of the most recent meta-analysis in 2007. Read More

    Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy.
    Aliment Pharmacol Ther 2017 Oct 17;46(8):722-730. Epub 2017 Aug 17.
    Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan.
    Background: Lenalidomide has immunomodulatory and anti-angiogenic effects and showed moderate anti-tumour efficacy in patients with. advanced hepatocellular carcinoma (HCC) AIM: To explore potential biomarkers of lenalidomide efficacy as second-line therapy for HCC.

    Methods: Eligible patients were diagnosed with advanced HCC, documented progression on sorafenib, and Child-Pugh class A liver function. Read More

    1 OF 163